All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Molecular Targeted Therapies 1” took place.
One of the posters on display (3150 / 10) was titled “PLCG2 C2-domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib” by Dan Jones from The Ohio State University, Columbus, OH, and colleagues.
The group analyzed all peripheral blood samples from CLL patients, with suitable depth of sequencing coverage, submitted to the Ohio State University James Polaris Molecular Laboratory.
The poster was summarized by stating that a high rate of co-occurrence of BTK codon 481 and PLCG2 mutations was found in samples from CLL patients unresponsive to ibrutinib. The group hypothesize that “multistep PLCG2 mutational activity may underlie resistance in many patients.” The authors also concluded by stating that they identified a novel mutation hotspot – the PLCG2 C2 domain – which often co-occurs with or after BTK codon 481 and/or PLCG2 SH2/SH3 mutations. Finally, it was also found that BTK mutations segregate with different PLCG2 germline polymorphisms.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox